Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1432-0843
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations ; volume:84 ; number:2 ; day:27 ; month:5 ; year:2019 ; pages:255-263 ; date:8.2019
Cancer chemotherapy and pharmacology ; 84, Heft 2 (27.5.2019), 255-263, 8.2019

Creator
Nobre, Carmen F.
Newman, Matthew J.
DeLisa, Anne
Newman, Pauline
Contributor
SpringerLink (Online service)

DOI
10.1007/s00280-019-03875-6
URN
urn:nbn:de:101:1-2019120812125891395890
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 11:02 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Nobre, Carmen F.
  • Newman, Matthew J.
  • DeLisa, Anne
  • Newman, Pauline
  • SpringerLink (Online service)

Other Objects (12)

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Management of relapsed-refractory diffuse large B cell lymphoma

Management of relapsed-refractory diffuse large B cell lymphoma

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma

Update on the management of relapsed/refractory chronic lymphocytic leukemia

Update on the management of relapsed/refractory chronic lymphocytic leukemia

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia

Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports

Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports

Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma

Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia

Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia

Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia

Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia

Related objects